Option chain shows key data for Marker Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Marker Therapeutics.

Marker Therapeutics (NASDAQ:MRKR) Stock, Option Chain

Marker Therapeutics

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

wall street chart shutter2

News

Initiation

Markets

Analyst Ratings

Trading Ideas

ABEO

FLNC

KRYS

MRKR

SNDK

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Biotech

Health Care

General

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. 

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Movers

Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter 

Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?

Marker Therapeutics Inc

Management

Press Releases

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Earnings

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Financing

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

KRRO

PLRX

Aprea Therapeutics

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

GlycoMimetics

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Immuron Limited - American Depositary Shares

Immuron

IN8bio

Leap Therapeutics

Moleculin Biotech

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

Palatin Techs

SAB Biotherapeutics

Spruce Biosciences

Synlogic

WBB Securities

Canaccord Genuity

Ladenburg Thalmann

Comments

Marker Therapeutics

Marker Therapeutics (MRKR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga